Medical Cannabis Legalization: No Contribution to Rising Stimulant Rates in the USA
Pharmacopsychiatry · 01.11.2023 · 56 (06) · 214-218
DOI: 10.1055/a-2152-7757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacopsychiatry, erschienen am 01.11.2023. Verfasst von Garrett D Alexander und 4 weiteren Autor:innen. Beteiligte Einrichtung: Geisinger Commonwealth School of Medicine, Scranton, PA, United States. Hauptthemen laut MEDLINE: Medical Marijuana, Central Nervous System Stimulants, Methylphenidate, Attention Deficit Disorder with Hyperactivity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Introduction
There has been a pronounced increase in the use of Schedule II stimulants to treat attention-deficit hyperactivity disorder (ADHD) in the United States over the last two decades. Interestingly, chronic medical cannabis (MC) use can present with cognitive impairments that resemble ADHD symptoms. This study aimed to determine if MC legalization increased prescription stimulant distribution.
Methods
Information on the distribution of methylphenidate, amphetamine, and lisdexamfetamine for 2006 to 2021 was extracted from the Drug Enforcement Administration’s comprehensive database and the three-year population-corrected slopes of stimulant distribution before and after MC program implementation were compared.
Results
We found a significant main effect of time (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Geisinger Commonwealth School of Medicine, Scranton, PA, United States.
- Behavioral Health Initiative, Scranton, PA, United States.
- Center for Pharmacy Innovation and Outcomes, Forty Fort, PA, United States.
Zitieren
APA
Alexander, G. D., Cavanah, L. R., Goldhirsh, J. L., Huey, L. Y., & Piper, B. J. (2023). Medical Cannabis Legalization: No Contribution to Rising Stimulant Rates in the USA. Pharmacopsychiatry, 56(06), 214-218. https://doi.org/10.1055/a-2152-7757
Vancouver
Alexander GD, Cavanah LR, Goldhirsh JL, Huey LY, Piper BJ. Medical Cannabis Legalization: No Contribution to Rising Stimulant Rates in the USA. Pharmacopsychiatry. 2023;56(06):214-218. doi:10.1055/a-2152-7757
BibTeX
@article{Alexander2023,
author = {Alexander, Garrett D and Cavanah, Luke R and Goldhirsh, Jessica L and Huey, Leighton Y and Piper, Brian J},
title = {Medical Cannabis Legalization: No Contribution to Rising Stimulant Rates in the USA},
journal = {Pharmacopsychiatry},
year = {2023},
volume = {56},
number = {06},
pages = {214--218},
doi = {10.1055/a-2152-7757}
}
EUVIMED